vs
Orthofix Medical Inc.（OFIX）与PROSPERITY BANCSHARES INC（PB）财务数据对比。点击上方公司名可切换其他公司
PROSPERITY BANCSHARES INC的季度营收约是Orthofix Medical Inc.的1.7倍（$367.6M vs $219.9M），PROSPERITY BANCSHARES INC净利率更高（31.6% vs -1.0%，领先32.6%），过去两年PROSPERITY BANCSHARES INC的营收复合增速更高（19.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Prosperity Bancshares Inc.是总部位于美国得克萨斯州休斯顿的银行控股公司，业务覆盖得克萨斯州及俄克拉荷马州中部。截至2019年12月31日，公司共运营285家分支机构，广泛分布在休斯顿、达拉斯-沃斯堡都会区及得州南部、东部、中部、西部等区域。
OFIX vs PB — 直观对比
营收规模更大
PB
是对方的1.7倍
$219.9M
净利率更高
PB
高出32.6%
-1.0%
两年增速更快
PB
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $367.6M |
| 净利润 | $-2.2M | $116.3M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | 31.6% |
| 营收同比 | 2.0% | — |
| 净利润同比 | 92.4% | -10.7% |
| 每股收益（稀释后） | $-0.05 | $1.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPB
| Q1 26 | — | $367.6M | ||
| Q4 25 | $219.9M | $275.0M | ||
| Q3 25 | $205.6M | $273.4M | ||
| Q2 25 | $203.1M | $267.7M | ||
| Q1 25 | $193.6M | $265.4M | ||
| Q4 24 | $215.7M | $267.8M | ||
| Q3 24 | $196.6M | $261.7M | ||
| Q2 24 | $198.6M | $258.8M |
净利润OFIXPB
| Q1 26 | — | $116.3M | ||
| Q4 25 | $-2.2M | $139.9M | ||
| Q3 25 | $-22.8M | $137.6M | ||
| Q2 25 | $-14.1M | $135.2M | ||
| Q1 25 | $-53.1M | $130.2M | ||
| Q4 24 | $-29.1M | $130.1M | ||
| Q3 24 | $-27.4M | $127.3M | ||
| Q2 24 | $-33.4M | $111.6M |
毛利率OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 65.1% | ||
| Q3 25 | -8.3% | 64.4% | ||
| Q2 25 | -7.9% | 64.3% | ||
| Q1 25 | -25.2% | 62.7% | ||
| Q4 24 | -5.3% | 62.0% | ||
| Q3 24 | -9.6% | 62.1% | ||
| Q2 24 | -12.5% | 55.2% |
净利率OFIXPB
| Q1 26 | — | 31.6% | ||
| Q4 25 | -1.0% | 50.9% | ||
| Q3 25 | -11.1% | 50.3% | ||
| Q2 25 | -6.9% | 50.5% | ||
| Q1 25 | -27.4% | 49.1% | ||
| Q4 24 | -13.5% | 48.6% | ||
| Q3 24 | -13.9% | 48.6% | ||
| Q2 24 | -16.8% | 43.1% |
每股收益（稀释后）OFIXPB
| Q1 26 | — | $1.16 | ||
| Q4 25 | $-0.05 | $1.48 | ||
| Q3 25 | $-0.57 | $1.45 | ||
| Q2 25 | $-0.36 | $1.42 | ||
| Q1 25 | $-1.35 | $1.37 | ||
| Q4 24 | $-0.76 | $1.36 | ||
| Q3 24 | $-0.71 | $1.34 | ||
| Q2 24 | $-0.88 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $8.2B |
| 总资产 | $850.6M | $43.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — |
总债务OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXPB
| Q1 26 | — | $8.2B | ||
| Q4 25 | $450.0M | $7.6B | ||
| Q3 25 | $442.5M | $7.7B | ||
| Q2 25 | $458.3M | $7.6B | ||
| Q1 25 | $458.3M | $7.5B | ||
| Q4 24 | $503.1M | $7.4B | ||
| Q3 24 | $525.9M | $7.4B | ||
| Q2 24 | $546.0M | $7.3B |
总资产OFIXPB
| Q1 26 | — | $43.6B | ||
| Q4 25 | $850.6M | $38.5B | ||
| Q3 25 | $832.6M | $38.3B | ||
| Q2 25 | $837.2M | $38.4B | ||
| Q1 25 | $823.1M | $38.8B | ||
| Q4 24 | $893.3M | $39.6B | ||
| Q3 24 | $867.9M | $40.1B | ||
| Q2 24 | $882.0M | $39.8B |
负债/权益比OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $78.3M | ||
| Q3 25 | $12.4M | $194.8M | ||
| Q2 25 | $11.6M | $98.2M | ||
| Q1 25 | $-18.4M | $178.2M | ||
| Q4 24 | $23.7M | $-205.8M | ||
| Q3 24 | $11.7M | $274.6M | ||
| Q2 24 | $9.0M | $216.5M |
自由现金流OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $68.5M | ||
| Q3 25 | $2.5M | $185.7M | ||
| Q2 25 | $4.5M | $91.8M | ||
| Q1 25 | $-25.1M | $171.1M | ||
| Q4 24 | $15.2M | $-210.7M | ||
| Q3 24 | $6.3M | $270.2M | ||
| Q2 24 | $-360.0K | $211.8M |
自由现金流率OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 24.9% | ||
| Q3 25 | 1.2% | 67.9% | ||
| Q2 25 | 2.2% | 34.3% | ||
| Q1 25 | -13.0% | 64.5% | ||
| Q4 24 | 7.0% | -78.7% | ||
| Q3 24 | 3.2% | 103.3% | ||
| Q2 24 | -0.2% | 81.8% |
资本支出强度OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 3.6% | ||
| Q3 25 | 4.8% | 3.3% | ||
| Q2 25 | 3.5% | 2.4% | ||
| Q1 25 | 3.5% | 2.7% | ||
| Q4 24 | 4.0% | 1.8% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 4.7% | 1.8% |
现金转化率OFIXPB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 1.37× | ||
| Q4 24 | — | -1.58× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 1.94× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
